Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17369331 | 0.87 | ESR1 (0.50) | ALDH1A1LMNAL3MBTL1KDM4ECYP1A2 | |
| SCHEMBL17362621 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDMAPTLMNA | |
| SCHEMBL17362904 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDMAPTLMNA | |
| SCHEMBL22302580 | 0.83 | ALDH1A1 (0.44) | ALDH1A1GAAHPGDMAPTL3MBTL1 | |
| SCHEMBL10003063 | 0.79 | ALDH1A1 (0.48) | ALDH1A1GAAHPGDMAPTLMNA | |
| SCHEMBL17362887 | 0.78 | KDM4E (0.43) | GAAHPGDKDM4ECYP1A2CYP2C9 | |
| SCHEMBL257250 | 0.78 | ALDH1A1 (0.62) | ALDH1A1GAAHPGDMAPTLMNA | |
| SCHEMBL11191069 | 0.76 | CYP1A2 (0.55) | ALDH1A1GAAHPGDMAPTLMNA | |
| SCHEMBL17362522 | 0.76 | MAP2K1 (0.40) | ALDH1A1GAAHPGDMAPTKDM4E | |
| SCHEMBL24392298 | 0.75 | CYP1A2 (0.49) | ALDH1A1GAAHPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137653-A1 | METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES | MELLICELL, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4380566-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076354-A | Methods of treating migraine with MNK inhibitors | 4E治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4363419-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117980305-A | Spirocyclic pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof | 4E治疗公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-111253397-B | MNK inhibitors | 上海迪诺医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NIM1K, NEK1, NEK11 | ALDH1A1 2161/4885GAA 3338/4885HPGD 1431/4885 |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | ALDH1A1 4285/4885GAA 1292/4885HPGD 4193/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | ALDH1A1 4285/4885GAA 1292/4885HPGD 4193/4885 |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | DMPK, NIM1K, CAMKK2 | ALDH1A1 4381/4885GAA 1219/4885HPGD 2771/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | ALDH1A1 1693/4885GAA 1147/4885HPGD 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.